The U.S. DEA is considering reclassifying marijuana from Schedule I to Schedule III, easing research into its therapeutic effects.

Reclassification could affect legality of medical marijuana prescriptions in states where it's legal.

Experts warn the change should not be seen as an endorsement of safety, citing risks like addiction and mental illness.

Current research on marijuana's health impacts is limited due to regulatory hurdles and concerns over its increasing potency.

The reclassification could acknowledge marijuana's benefits in treating symptoms of serious illnesses, despite its known risks.

Final decision awaits review by the White House OMB and a public comment period.

Advocates emphasize that beyond reclassification, decriminalization and reparations are needed for those affected by past cannabis laws.